Search results
5 wrz 2024 · Anti-Ro/SSA antibodies may be the only autoantibodies present in a subset of patients with antinuclear antibody (ANA)-negative SLE. Additionally, anti-Ro/SSA antibodies (with or without anti-La/SSB antibodies) identify pregnant women who are at increased risk of having a child with neonatal lupus (NL).
- References
Anti-Ro/SSA antibodies may be the only autoantibodies...
- Medline
Recombinant SS-A/Ro antigen produced in bacteria proved to...
- Robert H Shmerling, MD
The anti-Ro/SSA and anti-La/SSB antigen-antibody systems....
- Antibodies to Double-Stranded (ds)DNA, Sm, and U1 RNP
{{configCtrl2.info.metaDescription}}
- Antiribosomal P Protein Antibodies
Gerli R, Caponi L. Anti-ribosomal P protein antibodies....
- References
26 mar 2018 · Anti-Ro (also called anti-SSa) and anti-La (also called anti-SSb) AAbs are often associated with SS but can also occur in SLE with a prevalence between 36 and 64% and between 8 and 33.6% for anti-Ro AAb and anti-La AAb, respectively (37, 38, 61, 75, 76).
6 gru 2012 · Anti-Ro/SSA antibodies are among the most frequently detected autoantibodies against extractable nuclear antigens and have been associated with systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS).
Emerging evidence suggests an arrhythmogenic effect of Anti-Ro/SSA (anti-Ro) and anti-La/SSB (anti-La) antibodies in adults, potentially involving a subclinical intracardiac inflammatory process.
30 lis 2023 · Anti-Ro antibodies are found in the majority of patients with secondary Sjögrens syndrome whatever the primary disease. In SS, anti-Ro (usually associated with anti-La) has been related to manifestations such as vasculitis, anaemia, thrombocytopaenia and lymphopaenia.
14 lip 2020 · The patients with anti-Ro antibodies can be symptomatic or completely asymptomatic. There are some women at risk of having positive anti-Ro and/or anti-La antibodies especially when diseases like SLE, SS, rheumatoid arthritis or mixed connective tissue disease have already been diagnosed.
23 lut 2020 · We conditionally recommend treating all women who are positive for anti-Ro/SSA and/or anti-La/SSB antibodies with HCQ during pregnancy. This is based on early and limited data and the low risk profile of HCQ.
